Univariate and multivariate analysis for transplant outcomes
| Outcomes . | Relapse/progression . | NRM . | PFS . | OS . | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Analysis . | Univariate . | Multivariate . | Univariate . | Multivariate . | Univariate . | Multivariate . | Univariate . | Multivariate . | ||||||||||
| Variables . | n . | HR (95%CI) . | P . | HR (95%CI) . | P . | HR (95%CI) . | P . | HR (95%CI) . | P . | HR (95%CI) . | P . | HR (95%CI) . | P . | HR (95%CI) . | P . | HR (95%CI) . | P . | |
| Age at allo-HCT (years) | <60 | 41 | 1 | .61 | 1 | .48 | 1 | .50 | 1 | .25 | 1 | .22 | 1 | .16 | 1 | .09 | ||
| ≥60 | 49 | 1.17 (0.64-2.15) | 1.35 (0.59-3.09) | 1.38 (0.54-3.50) | 1.34 (0.82-2.21) | 1.39 (0.82-2.37) | 1.49 (0.86-2.57) | 1.68 (0.92-3.07) | ||||||||||
| Gender | Female | 40 | 1 | .88 | 1 | .43 | 1 | .23 | 1 | .40 | ||||||||
| Male | 50 | 1.04 (0.57-1.92) | 1.39 (0.62-3.15) | 1.36 (0.83-2.23) | 1.26 (0.73-2.16) | |||||||||||||
| ATL type | Lymphoma | 25 | 1 | .16 | 1 | .052 | 1 | .92 | 1 | .51 | ||||||||
| Acute | 65 | 1.76 (0.81-3.85) | 0.44 (0.20-1.01) | 1.03 (0.60-1.78) | 0.82 (0.46-1.47) | |||||||||||||
| mATL-PI at diagnosis | Low | 30 | 1 | 1 | 1 | 1 | 1 | |||||||||||
| Intermediate | 52 | 1.65 (0.80-3.41) | .18 | 1.84 (0.78-4.33) | .16 | 0.80 (0.34-1.84) | .59 | 1.31 (0.75-2.26) | .34 | 1.34 (0.73-2.47) | .35 | |||||||
| High | 8 | 2.50 (0.83-7.48) | .10 | 3.20 (1.14-8.96) | .027 | 0.38 (0.05-3.15) | .37 | 1.61 (0.64-4.03) | .31 | 2.14 (0.83-5.54) | .12 | |||||||
| Induction chemotherapy | CHOP-like regimens | 11 | 1 | .5 | 1 | .3 | 1 | .03 | 1 | 0.006 | 1 | .003 | 1 | .004 | ||||
| mLSG15 | 79 | 0.74 (0.32-1.75) | 0.55 (0.18-1.69) | 0.46 (0.23-0.91) | 0.35 (0.16-0.74) | 0.34 (0.17-0.69) | 0.31 (0.14-0.69) | |||||||||||
| Number of cycles of chemotherapy before allo-HCT | ≤3 | 61 | 1 | .64 | 1 | .85 | 1 | .67 | 1 | .64 | ||||||||
| >3 | 29 | 1.17 (0.61-2.22) | 0.92 (0.38-2.22) | 1.12 (0.66-1.89) | 1.14 (0.65-2.02) | |||||||||||||
| Time to allo- HCT (day) | <128 | 43 | 1 | .087 | 1 | .72 | 1 | .073 | 1 | .33 | ||||||||
| ≥128 | 47 | 0.58 (0.31-1.08) | 1.16 (0.51-2.63) | 0.64 (0.39-1.04) | 0.76 (0.45-1.31) | |||||||||||||
| Status at allo-HCT | CR | 41 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||
| PR | 28 | 1.10 (0.53-2.30) | .80 | 1.07 (0.50-2.26) | .87 | 1.71 (0.72-4.12) | .22 | 1.71 (0.73-4.03) | .22 | 1.45 (0.81-2.59) | .21 | 1.48 (0.81-2.67) | .2 | 1.40 (0.73-2.67) | .31 | 1.37 (0.71-2.65) | .35 | |
| SD/PD | 21 | 2.88 (1.36-6.12) | .006 | 2.63 (1.08-6.44) | .034 | 0.89 (0.27-2.99) | .85 | 1.03 (0.29-3.71) | .96 | 2.87 (1.56-5.29) | <.001 | 3.05 (1.60-5.81) | <.001 | 2.97 (1.55-5.71) | .001 | 3.97 (1.95-8.09) | <.001 | |
| Donor | Unrelated | 26 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||
| Related | 14 | 1.54 (0.54-4.40) | .42 | 0.95 (0.24-3.78) | .94 | 1.05 (0.38-2.96) | .92 | 1.15 (0.44-3.03) | .78 | 1.43 (0.67-3.06) | .36 | 1.32 (0.60-2.91) | .50 | 1.23 (0.56-2.72) | .60 | 1.21 (0.53-2.78) | .65 | |
| CB | 30 | 2.92 (1.26-6.75) | .013 | 2.37 (0.93-6.03) | .071 | 0.37 (0.11-1.22) | .10 | 0.37 (0.11-1.29) | .12 | 1.83 (1.97-3.45) | .061 | 1.68 (0.85-3.33) | .14 | 1.00 (0.50-1.98) | 1.00 | 0.82 (0.39-1.73) | .61 | |
| Haplo | 20 | 1.30 (0.51-3.32) | .59 | 0.88 (0.30-2.59) | .82 | 0.73 (0.25-2.13) | .57 | 0.83 (0.27-2.58) | .75 | 1.03 (0.50-2.12) | .94 | 0.75 (0.35-1.62) | .47 | 0.88 (0.41-1.90) | .74 | 0.63 (0.28-1.40) | .26 | |
| Conditioning therapy | MAC | 14 | 1 | 1 | 1 | 1 | ||||||||||||
| Flu/Bu- based RIC | 16 | 0.57 (0.19-1.71) | .32 | 1.44 (0.45-4.61) | .54 | 0.74 (0.32-1.67) | .46 | 1.14 (0.46-2.78) | .78 | |||||||||
| Flu/Mel- based RIC | 58 | 0.98 (0.45-2.16) | .97 | 0.70 (0.22-2.19) | .54 | 0.86 (0.44-1.69) | .66 | 0.91 (0.42-1.99) | .82 | |||||||||
| Outcomes . | Relapse/progression . | NRM . | PFS . | OS . | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Analysis . | Univariate . | Multivariate . | Univariate . | Multivariate . | Univariate . | Multivariate . | Univariate . | Multivariate . | ||||||||||
| Variables . | n . | HR (95%CI) . | P . | HR (95%CI) . | P . | HR (95%CI) . | P . | HR (95%CI) . | P . | HR (95%CI) . | P . | HR (95%CI) . | P . | HR (95%CI) . | P . | HR (95%CI) . | P . | |
| Age at allo-HCT (years) | <60 | 41 | 1 | .61 | 1 | .48 | 1 | .50 | 1 | .25 | 1 | .22 | 1 | .16 | 1 | .09 | ||
| ≥60 | 49 | 1.17 (0.64-2.15) | 1.35 (0.59-3.09) | 1.38 (0.54-3.50) | 1.34 (0.82-2.21) | 1.39 (0.82-2.37) | 1.49 (0.86-2.57) | 1.68 (0.92-3.07) | ||||||||||
| Gender | Female | 40 | 1 | .88 | 1 | .43 | 1 | .23 | 1 | .40 | ||||||||
| Male | 50 | 1.04 (0.57-1.92) | 1.39 (0.62-3.15) | 1.36 (0.83-2.23) | 1.26 (0.73-2.16) | |||||||||||||
| ATL type | Lymphoma | 25 | 1 | .16 | 1 | .052 | 1 | .92 | 1 | .51 | ||||||||
| Acute | 65 | 1.76 (0.81-3.85) | 0.44 (0.20-1.01) | 1.03 (0.60-1.78) | 0.82 (0.46-1.47) | |||||||||||||
| mATL-PI at diagnosis | Low | 30 | 1 | 1 | 1 | 1 | 1 | |||||||||||
| Intermediate | 52 | 1.65 (0.80-3.41) | .18 | 1.84 (0.78-4.33) | .16 | 0.80 (0.34-1.84) | .59 | 1.31 (0.75-2.26) | .34 | 1.34 (0.73-2.47) | .35 | |||||||
| High | 8 | 2.50 (0.83-7.48) | .10 | 3.20 (1.14-8.96) | .027 | 0.38 (0.05-3.15) | .37 | 1.61 (0.64-4.03) | .31 | 2.14 (0.83-5.54) | .12 | |||||||
| Induction chemotherapy | CHOP-like regimens | 11 | 1 | .5 | 1 | .3 | 1 | .03 | 1 | 0.006 | 1 | .003 | 1 | .004 | ||||
| mLSG15 | 79 | 0.74 (0.32-1.75) | 0.55 (0.18-1.69) | 0.46 (0.23-0.91) | 0.35 (0.16-0.74) | 0.34 (0.17-0.69) | 0.31 (0.14-0.69) | |||||||||||
| Number of cycles of chemotherapy before allo-HCT | ≤3 | 61 | 1 | .64 | 1 | .85 | 1 | .67 | 1 | .64 | ||||||||
| >3 | 29 | 1.17 (0.61-2.22) | 0.92 (0.38-2.22) | 1.12 (0.66-1.89) | 1.14 (0.65-2.02) | |||||||||||||
| Time to allo- HCT (day) | <128 | 43 | 1 | .087 | 1 | .72 | 1 | .073 | 1 | .33 | ||||||||
| ≥128 | 47 | 0.58 (0.31-1.08) | 1.16 (0.51-2.63) | 0.64 (0.39-1.04) | 0.76 (0.45-1.31) | |||||||||||||
| Status at allo-HCT | CR | 41 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||
| PR | 28 | 1.10 (0.53-2.30) | .80 | 1.07 (0.50-2.26) | .87 | 1.71 (0.72-4.12) | .22 | 1.71 (0.73-4.03) | .22 | 1.45 (0.81-2.59) | .21 | 1.48 (0.81-2.67) | .2 | 1.40 (0.73-2.67) | .31 | 1.37 (0.71-2.65) | .35 | |
| SD/PD | 21 | 2.88 (1.36-6.12) | .006 | 2.63 (1.08-6.44) | .034 | 0.89 (0.27-2.99) | .85 | 1.03 (0.29-3.71) | .96 | 2.87 (1.56-5.29) | <.001 | 3.05 (1.60-5.81) | <.001 | 2.97 (1.55-5.71) | .001 | 3.97 (1.95-8.09) | <.001 | |
| Donor | Unrelated | 26 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||
| Related | 14 | 1.54 (0.54-4.40) | .42 | 0.95 (0.24-3.78) | .94 | 1.05 (0.38-2.96) | .92 | 1.15 (0.44-3.03) | .78 | 1.43 (0.67-3.06) | .36 | 1.32 (0.60-2.91) | .50 | 1.23 (0.56-2.72) | .60 | 1.21 (0.53-2.78) | .65 | |
| CB | 30 | 2.92 (1.26-6.75) | .013 | 2.37 (0.93-6.03) | .071 | 0.37 (0.11-1.22) | .10 | 0.37 (0.11-1.29) | .12 | 1.83 (1.97-3.45) | .061 | 1.68 (0.85-3.33) | .14 | 1.00 (0.50-1.98) | 1.00 | 0.82 (0.39-1.73) | .61 | |
| Haplo | 20 | 1.30 (0.51-3.32) | .59 | 0.88 (0.30-2.59) | .82 | 0.73 (0.25-2.13) | .57 | 0.83 (0.27-2.58) | .75 | 1.03 (0.50-2.12) | .94 | 0.75 (0.35-1.62) | .47 | 0.88 (0.41-1.90) | .74 | 0.63 (0.28-1.40) | .26 | |
| Conditioning therapy | MAC | 14 | 1 | 1 | 1 | 1 | ||||||||||||
| Flu/Bu- based RIC | 16 | 0.57 (0.19-1.71) | .32 | 1.44 (0.45-4.61) | .54 | 0.74 (0.32-1.67) | .46 | 1.14 (0.46-2.78) | .78 | |||||||||
| Flu/Mel- based RIC | 58 | 0.98 (0.45-2.16) | .97 | 0.70 (0.22-2.19) | .54 | 0.86 (0.44-1.69) | .66 | 0.91 (0.42-1.99) | .82 | |||||||||